Companies / BOC Sciences / Tafasitamab
BOC Sciences

Tafasitamab | BOC Sciences

Tafasitamab is a humanized FC-modified monoclonal antibody that binds to CD19, which is broadly expressed on the surface of B cells. Tafasitamab is indicated for the treatment of B cell malignancies, such as non-Hodgkin's lymphoma (NHL), including diffuse large B cell lymphoma (DLBCL), indolent lymphomas like follicular lymphoma (FL) and marginal zone lymphomas (MZL), as well as chronic lymphocytic leukemia (CLL).

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.